Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease


The purpose of this study is to determine whether matrix metalloproteinases are associated with atherosclerosis in the different stages of chronic kidney disease.

Full Title of Study: “The Role of Matrix Metalloproteinases -2 and -9 in Atherosclerosis of Patients With Chronic Kidney Disease”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: May 2016

Detailed Description

The purpose of this study is to determine the correlation of matrix metalloproteinases and atherosclerosis of chronic kidney disease. Patients with diabetes mellitus type 2,as a non-inflammatory leading cause of end stage renal failure and patients with chronic glomerulonephritis and similar course of proteinuria,as an inflammatory leading cause of end stage renal failure are enrolled.

Arms, Groups and Cohorts

  • Diabetic nephropathy
    • Diabetic nephropathy in patients with type 2 diabetes
  • chronic glomerulonephritis
    • chronic glomerulonephritis in patients without diabetes mellitus
  • controls
    • participants without diabetic nephropathy and chronic glomerulonephritis

Clinical Trial Outcome Measures

Primary Measures

  • Association of matrix metalloproteinases with atherosclerosis in patients with chronic kidney disease
    • Time Frame: two years
    • Matrix metalloproteinases associated with atherosclerosis in chronic kidney disease;patients with diabetes mellitus type 2 and others with chronic glomerulonephritis.Serum levels of MMPs-2 and -9 are measured by an ELISA system.Intima Media Thickness(IMT) of carotid and femoral arteries is measured with a high resolution ultrasonography.

Secondary Measures

  • Matrix metalloproteinases and atherosclerosis associated with pro-inflammatory and oxidative stress markers in chronic kidney disease
    • Time Frame: two years
    • Matrix metalloproteinases associated with atherosclerosis markers,pro-inflammatory markers and markers of oxidative stress in chronic kidney disease

Participating in This Clinical Trial

Inclusion Criteria

  • Chronic kidney disease
  • Diabetes mellitus type 2

Exclusion Criteria

  • Malignancy

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Aristotle University Of Thessaloniki
  • Collaborator
    • AHEPA University Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Grigorios G. DIMAS, Doctor/PhD Candidate – Aristotle University Of Thessaloniki
  • Overall Official(s)
    • Grigorios G. Dimas, MD, Principal Investigator, AHEPA University Hospital,Medical School of Aristotle University of Thessaloniki
  • Overall Contact(s)
    • Grigorios G. Dimas, +0030 6972321534,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.